October 25, 2018 09:02 PM EDTUpdated 09:45 AM
Bioregnum
Opinion

Fight! Trump kicks off a war of words with the drug lob­by, propos­ing to peg Medicare prices to over­seas rates

Pres­i­dent Don­ald Trump has just fired an­oth­er shot across the bow of the glob­al bio­phar­ma in­dus­try. And the in­dus­try quick­ly fired back in what promis­es …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA picks con­tro­ver­sial doc­tor Vinay Prasad as CBER di­rec­tor, in about-face from Marks

Biotech stocks plunge and in­dus­try fig­ures left to won­der af­ter Prasad's FDA ap­point­ment

What Vinay Prasad means for CBER, vac­cines, drug ap­provals and more

Even as ques­tions grow over RFK Jr.'s vac­cine pol­i­cy, BioN­Tech does­n't see ‘near-term’ im­pact

No­vo Nordisk trims growth fore­cast as GLP-1 com­pounder ban yet to go live

sponsored

In one of the riski­est in­dus­tries — Biotech — a sure­fire way to neu­tral­ize some of that risk emerges

A service from the Financial Times